UB Paderborn / Katalog / Suche / in CDI

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

The Lancet (British edition), 2016-08, Vol.388 (10044), p.576-585

2016

Volltextzugriff (PDF)

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Haematologica (Roma), 2019-01, Vol.104 (1), p.93-101

2019

Volltextzugriff (PDF)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Current treatment options in oncology, 2018-03, Vol.19 (3), p.15-13, Article 15

Laneuville, Pierre

2018

Volltextzugriff (PDF)

Stopping second-generation TKIs in CML

Blood, 2017-02, Vol.129 (7), p.805-806

Laneuville, Pierre

2017

Volltextzugriff (PDF)

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

The New England journal of medicine, 2006-06, Vol.354 (24), p.2623-2624

2006

Volltextzugriff (PDF)

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches

Neural regeneration research, 2018-11, Vol.13 (11), p.1871-1874

2018

Volltextzugriff (PDF)

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A381-A381

2020

Volltextzugriff (PDF)

High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis

Blood, 2012-11, Vol.120 (21), p.3776-3776

Laneuville, Pierre

2012

Volltextzugriff (PDF)

Impaired apoptosis underlying lymphoproliferative disease in a patient with haploinsufficient NFKB1 deficiency

British journal of haematology, 2024-10

2024

Volltextzugriff (PDF)

Secondary intestinal lymphangiectasia due to multiple myeloma

Gastrointestinal endoscopy, 2011-09, Vol.74 (3), p.718-720

2011

Volltextzugriff (PDF)

Treatment of Progressive Multifocal Leukoencephalopathy with IL-2 and Mirtazapine

Journal of clinical immunology, 2024-04, Vol.44 (4), p.97, Article 97

2024

Volltextzugriff (PDF)

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

Blood, 2021-11, Vol.138 (Supplement 1), p.2572-2572

2021

Volltextzugriff (PDF)

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

Blood, 2013-05, Vol.121 (22), p.4439-4442

2013

Volltextzugriff (PDF)

The Cost-Effectiveness of Stem Cell Transplantations from Unrelated Donors in Adult Patients with Acute Leukemia

Value in health, 2007-07, Vol.10 (4), p.247-255

2007

Volltextzugriff (PDF)

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

Annals of neurology, 2013-03, Vol.73 (3), p.341-354

2013

Volltextzugriff (PDF)

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Blood, 2022-11, Vol.140 (Supplement 1), p.6778-6779

2022

Volltextzugriff (PDF)

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Blood, 2012-09, Vol.120 (13), p.2573-2580

2012

Volltextzugriff (PDF)

Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study

British journal of haematology, 2023-12, Vol.203 (5), p.781-791

2023

Volltextzugriff (PDF)

PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL

European journal of haematology, 2023-08, Vol.111 (2), p.191-200

2023

Volltextzugriff (PDF)

Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment

Current medical research and opinion, 2018-08, Vol.34 (8), p.1419-1430

2018

Volltextzugriff (PDF)

Featured Cover

European journal of haematology, 2023-08, Vol.111 (2), p.i-i

2023

Volltextzugriff (PDF)

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Blood, 2019-11, Vol.134 (Supplement_1), p.3236-3236

2019

Volltextzugriff (PDF)

Risk of infection in MPN patients in the era of C ovid‐ 19 : A prospective multicenter study of 257 patients from the CML‐MPN Q uebec R esearch G roup

American journal of hematology, 2021-06, Vol.96 (6)

2021

Volltextzugriff (PDF)

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Blood, 2020-11, Vol.136 (Supplement 1), p.16-16

2020

Volltextzugriff (PDF)

Isolated Bilateral Cranial Nerve Three Palsy as Unique Manifestation of CNS Spread of Burkitt Lymphoma (P01.058)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Stopping second-generation TKIs in CML

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis

Impaired apoptosis underlying lymphoproliferative disease in a patient with haploinsufficient NFKB1 deficiency

Secondary intestinal lymphangiectasia due to multiple myeloma

Treatment of Progressive Multifocal Leukoencephalopathy with IL-2 and Mirtazapine

Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

The Cost-Effectiveness of Stem Cell Transplantations from Unrelated Donors in Adult Patients with Acute Leukemia

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study

PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL

Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment

Featured Cover

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Risk of infection in MPN patients in the era of C ovid‐ 19 : A prospective multicenter study of 257 patients from the CML‐MPN Q uebec R esearch G roup

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Isolated Bilateral Cranial Nerve Three Palsy as Unique Manifestation of CNS Spread of Burkitt Lymphoma (P01.058)

Suchergebnisse filtern